COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

30 1 2025 06:30:33 提供 Nasdaq GlobeNewswire

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08 1 2025 15:14:32 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

18 12 2024 06:22:43 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

26 11 2024 06:30:22 提供 Nasdaq GlobeNewswire

Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

25 11 2024 06:30:49 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

13 11 2024 06:30:45 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

12 11 2024 06:30:38 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 10 2024 15:15:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 10 2024 11:55:00 提供 Nasdaq GlobeNewswire

Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 10 2024 06:30:27 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 10 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 9 2024 06:30:00 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 8 2024 06:31:24 提供 Nasdaq GlobeNewswire

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

08 8 2024 06:00:53 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

05 8 2024 06:30:19 提供 Nasdaq GlobeNewswire

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

29 7 2024 06:00:33 提供 Nasdaq GlobeNewswire

Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024

26 7 2024 15:11:52 提供 Nasdaq GlobeNewswire

Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC

02 7 2024 06:30:38 提供 Nasdaq GlobeNewswire